Agenus (AGEN) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 17, 2025, with voting on key proposals including director elections, amendments to equity and compensation plans, a one-time option exchange, executive compensation, and auditor ratification.

• The company faced significant challenges in 2024, including an FDA decision impacting its lead therapies, resulting in stock price decline, SEC investigation, and shareholder litigation.

• Cost-saving measures included workforce reductions, asset monetization, and shifting senior management compensation from cash to equity.

Voting matters and shareholder proposals

• Election of two Class I directors for three-year terms.

• Amendments to increase shares under the 2019 Equity Incentive Plan, Directors' Deferred Compensation Plan, and Employee Stock Purchase Plan.

• Approval of a one-time exchange of underwater options for new options at current market price.

• Non-binding advisory vote on executive compensation (Say-on-Pay).

• Ratification of KPMG LLP as independent auditor for 2025.

Board of directors and corporate governance

• Board consists of six members divided into three classes, with regular annual elections.

• Strong emphasis on independence, with a majority of directors classified as independent.

• Lead Director role provides independent oversight; CEO serves as Chairman.

• Five standing committees: Audit and Finance, Compensation, Corporate Governance and Nominating, Affiliate Transactions, and Executive.

• Annual board and committee self-evaluations and adherence to updated Code of Business Conduct and Ethics.